SB II

SB - got word that Dominic 'Nick' (formerly CSO - dir. biz development) recently joined Amgen. Do you know if he plans to bring former CSO colleagues with him?

 

SB - any updates on plans for amgen field obu - RSDs, DMs, alignment, drugs in bag, reps, RIF, etc?

 

Latest is the collapse of bone RD, DM and reps to CSO, either January 2015 or October 2015, savings of about 26% per rep, 31% by dm and nearly 35% by RD, huge cost savings at a time it is desperately needed, this will likely be announced in December of 2014, - SB

 

Not much change, reduction in SOC for RD and DM is a certainty and staff reductions as well, but all are VTP dependent, the more that say yes the less that get the RIF, -SB

 

SB - any updates on sales headcount in obu? One field force or two? How will negative news regarding krypolis today impact amgen obu... vs onyx? No plans for obu to go contract in q1 with bone, is there? Should we as reps stay or go?

 

Too early on impact to OBU or Onyx, it was assumed the EP's would be positive and that was the basis of the sizing, so you should expect it will be smaller than the 404 number that was planned, OBU goes to contract sales on a rep by rep basis staring in Q1 but not wholesale until end of Q3 2015 so there is time to find other things, -SB

 

SB - 404 out of how many? Will Onyx still be protected?

 

sb - what products will the amgen obu promote in 1/15? Will portfolio include
Tvec, Arinesp, Vectibix, Neupogen, Nplate?

 

So the entire BCBU will be switched to CSO? Not just the 120 that are being hired to promote CV?

 

What a bleak future at Amgen for those that had no intention of leaving.

Stay in INBU now, get fired or automatically lose 25% pay and degraded benefits over next couple of years as you get shuffled into CSO

Stay in OBU, face same fate as INBU, while kyprolis and T-Vec keep failing outcomes studies

Stay in BCBU, face same fate as INBU and OBU, and realize CSO will be pushing evo if they stick to what they say and Amgen finally focuses on PCPs after release of outcomes data in '18

Go to CV while Amgen loses PCSK9 race, a monthly dosing device, and any edge in efficacy

Stay in TO... weather the massacre...watch as Tony and Bob fly back in forth in their $60+ million jets that help them to struggle through '16

 

Any leader worth their salt would have realized the tremendous sacrifice people in this company have had to make over the years and would not have purchased yet ANTOHER jet to shove his personal prosperity into our face. Jets have NOTHING to do with biotech, and it would have been logically the very FIRST thing to contract out. Banker Bob is just a self serving money glutton and should not be running any scientific anything. He shouldn't get the 50 million bonus for eviscerating the company to artificially get the stock price up.

 

Amgen reps will not be selling the onyx drugs anyway and kyprolis will be fine.

 

SB:
- Who killed Kennedy?
- Was Obama really born in here?
- Was the moon landing legit or a mocked-up movie stage?
- Is there any truth to the rumor that Bob & Tony are lovers?
- How many licks does it really take to get to the center of a tootsie roll pop - we all know the owl cheated.
- Ginger or Mary Ann? If you're female...I'm sorry, can't come up with anything.
- Was Hong Kong Phooey really Henry, the mild-mannered janitor?

- Once you're gone, will you reveal your identity?

 

SB, INBU has multiple biosimilars coming to market in addition to Enbrels extended patent until 2026 and upcoming ILs for PsO ----- exec board still wants to move 50-75% to CSO and thinks people will stay there for less money, lower benefits and a non-Amgen name?

 

SB----woah!!! Where did that one come from? That wasn't the original plan. Dang, they were right when they said on our call that they hadn't really decided, huh? Am I reading this right? You were saying Bone health reps initially were fine, but now you are saying Prolia reps also going to be moved to CSO? Like SOON? Thanks for your intel as things progress.

 

T-Vec failed to meet a secondary endpoint in a study because their placebo study group did not have statistical significance (p=0.051). Besides one person not dying in the placebo group, the drug has done quite unbelievable.

 

funny stuff, yes I will, - SB

 

Bio-sims are still in discussion for commercial sales partner and while ETA has long patent it will get hurt by ADA and INF so it's patent means a bit less, IL-17 will be second or third to market, peak year sales of around 450M and that's in nearly 10 years and remember that IL-17 is a partner drug with AZ, AZ is potential home of bio-sims, - SB

 

It is one of two options back on the table yes, the timing and setbacks to EVO will impact all of the US Sales Forces, they are now assuming less revenue and it takes longer to peak for EVO, the result is in more pain and with new people leading the bone team they would like to hire more for CV and outsource prolia, - SB

 

SB, also, IS the Hokey Pokey really what it's all about?